Why the study?
Does combination therapy with antitachycardia pacemakers and automatic implantable cardioverter defibrillators effectively manage recurrent ventricular tachycardia in patients with drug-refractory pace-terminable sustained ventricular tachycardia?
Does combination therapy with antitachycardia pacemakers and automatic implantable cardioverter defibrillators effectively manage recurrent ventricular tachycardia in patients with drug-refractory pace-terminable sustained ventricular tachycardia?
Answers are grounded in this paper and cite their sources.
Combination therapy with antitachycardia pacemakers and automatic implantable cardioverter defibrillators can work synergistically to manage malignant ventricular arrhythmias in carefully selected patients.
The judicious use of antitachycardia pacemakers can enhance the benefits of automatic implantable cardioverter defibrillators in certain patients. Both devices were implanted in 10 highly selected patients with drug-refractory pace-terminable sustained ventricular tachycardia. During the observation period of 8 +/- 4.8 months, the automatic pacemakers detected 1,542 episodes of ventricular tachycardia and appropriately managed 1,373. The automatic implantable defibrillator was activated at least once in every patient; on two documented occasions, the defibrillator discharged because the automatic pacemaker accelerated the tachycardia. Concomitant antiarrhythmic drugs could be reduced but not withdrawn. With meticulous device programming and testing, the two systems in combination can work synergistically to manage malignant ventricular arrhythmias in carefully selected patients.
No takes yet. Share an insight, caveat, or question.
Masterson et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: